|
|
||||||||
J Thorac Cardiovasc Surg 2004;127:242-250
© 2004 The American Association for Thoracic Surgery
Surgery for congenital heart disease |
a Clinic for Cardiovascular Surgery, University Hospital of Geneva, Geneva, Switzerland
b Department of Pediatric Cardiology, University Hospital of Geneva, Geneva, Switzerland
Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.
Received for publication April 14, 2003; revisions received June 26, 2003; accepted for publication July 22, 2003.
* Address for reprints: Dr Jan T. Christenson, MA, MD, PD, FETCS, Clinic for Cardiovascular Surgery, University Hospital of Geneva, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland
jan.christenson{at}hcuge.ch
OBJECTIVE: Cryopreserved valved homograft has become the conduit of choice for right ventricular outflow tract reconstruction in pediatric cardiac surgery. Aortic homografts have been frequently used in pulmonary position, but accelerated aortic homograft fibrocalcification may occur. Blood group incompatibility between receiver and homograft donor may play a central role in this context.
METHODS: Between 1993 and 2000, 59 children (mean age 6.4 ± 4.4 years) received cryopreserved valved homografts for right ventricular outflow tract reconstruction and were followed from 2 to 10 years clinically, with echocardiography and chest radiography for detection of development of homograft calcifications. Seventeen patients were 3 years or younger. Fifty aortic (85%) and 9 pulmonary homografts were all used in pulmonary position. Thirty-three patients (56%) had the same blood group (ABO) as the homograft donor (iso group), and 26 were blood groupincompatible (non-iso group).
RESULTS: No deaths occurred during follow-up. Six patients (10.2%) required homograft replacement because of severe fibrocalcifications, and another 3 showed moderate homograft calcifications (5.1%) at last examination. Freedom from moderate to severe homograft calcification at 8 years (Kaplan-Meier) was 95.2% for the iso group and 72.9% for the non-iso group (P < .0001). Homograft calcifications occurred within 2 years of implantation in 6/9 patients (67%) in the non-iso group.
CONCLUSIONS: Blood group incompatibility between receiver and homograft donor seems to play an important role in the development of accelerated fibrocalcifications in cryopreserved homografts, particularly in the very young (3 years old or younger). Blood group compatibility should therefore be respected to avoid accelerated homograft fibrocalcifications.
This article has been cited by other articles:
![]() |
J. P.V. Zachariah, F. A. Pigula, J. E. Mayer Jr, and D. B. McElhinney Right ventricle to pulmonary artery conduit augmentation compared with replacement in young children. Ann. Thorac. Surg., August 1, 2009; 88(2): 574 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Hopkins, A. L. Jones, L. Wolfinbarger, M. A. Moore, A. A. Bert, and G. K. Lofland Decellularization reduces calcification while improving both durability and 1-year functional results of pulmonary homograft valves in juvenile sheep J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 907 - 913. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Feingold, P. D. Wearden, V. O. Morell, D. Galvis, and C. Galambos Expression of A and B Blood Group Antigens on Cryopreserved Homografts Ann. Thorac. Surg., January 1, 2009; 87(1): 211 - 214. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ando and Y. Takahashi Ten-year experience with handmade trileaflet polytetrafluoroethylene valved conduit used for pulmonary reconstruction. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 124 - 131. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Troost, B. Meyns, W. Daenen, F. Van de Werf, M. Gewillig, K. Van Deyk, P. Moons, and W. Budts Homograft survival after tetralogy of Fallot repair: determinants of accelerated homograft degeneration Eur. Heart J., October 2, 2007; 28(20): 2503 - 2509. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sierra, J. T. Christenson, N. H. Lahlaidi, M. Beghetti, and A. Kalangos Right Ventricular Outflow Tract Reconstruction: What Conduit to Use? Homograft or Contegra? Ann. Thorac. Surg., August 1, 2007; 84(2): 606 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Geissler, U. M. Fischer, S. Foerster, A. Krahwinkel, A. Antonyan, A. Kroener, K. Addicks, U. Mehlhorn, and W. Bloch Effect of Thawing on Nitric Oxide Synthase III and Apoptotic Markers in Cryopreserved Human Allografts Ann. Thorac. Surg., November 1, 2006; 82(5): 1742 - 1746. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Tavakkol, S. Gelehrter, C. S. Goldberg, E. L. Bove, E. J. Devaney, and R. G. Ohye Superior Durability of Synergraft Pulmonary Allografts Compared With Standard Cryopreserved Allografts Ann. Thorac. Surg., November 1, 2005; 80(5): 1610 - 1614. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Feier, F. Collart, O. Ghez, A. Riberi, T. Caus, B. Kreitmann, and D. Metras Risk Factors, Dynamics, and Cutoff Values for Homograft Stenosis After the Ross Procedure Ann. Thorac. Surg., May 1, 2005; 79(5): 1669 - 1675. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D. Affonso da Costa, P. M. Dohmen, D. Duarte, C. von Glenn, S. V. Lopes, H. H. Filho, M. B. Affonso da Costa, and W. Konertz Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 572 - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ketchedjian, A. L. Jones, P. Krueger, E. Robinson, K. Crouch, L. Wolfinbarger Jr, and R. Hopkins Recellularization of Decellularized Allograft Scaffolds in Ovine Great Vessel Reconstructions Ann. Thorac. Surg., March 1, 2005; 79(3): 888 - 896. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |